VivoSeq
Other

Real-World Study

0

Pipeline Programs

13

Active Trials

5

Companies Involved

Real-world Study is an early-stage landscape with 0 programs across 5 companies. The most active players are Biogen, Innovent Biologics (Suzhou) Co. Ltd., Boehringer Ingelheim.

Pipeline Metrics

Competitive Density

30/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

8/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

24

clinical trials

Unknown status7 · 29%
Recruiting6 · 25%
Not yet recruiting5 · 21%
Active, not recruiting2 · 8%
Completed2 · 8%
Terminated2 · 8%

Trial Activity

24 trials

Real-world Study Optimizing Nucleotide-analogues
Recruiting·HHuashan Hospital·N/A·NCT05937178·20,000 enrolled
A Real-World Study of Trastuzumab Rezetecan in HER2+ Solid Tumors
Active, not recruiting·LLixiaoling·N/A·NCT07387874·30 enrolled
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
Active, not recruiting·Roche logoRoche·N/A·NCT05476926·6,000 enrolled
A Real-world Study of Imraldi® Use
Completed·Biogen logoBiogen·N/A·NCT04089514·1,000 enrolled
Real-world Study on Adjuvant Octreotide Therapy in pNETs
Completed··N/A·NCT06080204·411 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)